Tower Research Capital (TRC)’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-40
Closed -$1.3K – 5408
2025
Q2
$1.3K Buy
+40
New +$1.11K ﹤0.01% 4831
2022
Q4
– Sell
-5
Closed -$7K – 6132
2022
Q3
$7K Buy
+5
New +$9.25K ﹤0.01% 4891

Other funds holding MTRI

Tower Research Capital (TRC)'s MTRI Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Mentari Therapeutics, Inc. Common Stock (MTRI) in Q3 2025, closing a stake of 40 shares — an estimated $1.3K sold.

Tower Research Capital (TRC) first reported a position in MTRI in Q3 2022 and held it in 2 quarters. The position peaked at $7K in Q3 2022. 7 funds tracked by Wall St. Rank hold MTRI as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Mentari Therapeutics, Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 40 Mentari Therapeutics, Inc. Common Stock shares in Q3 2025, an estimated $1.3K.
  • Tower Research Capital (TRC) first reported a position in Mentari Therapeutics, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Tower Research Capital (TRC)'s Mentari Therapeutics, Inc. Common Stock position peaked at $7K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.